+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Global T-cell lymphoma Market by Treatment (Chemotherapy, Corticosteroids, Retinoid), End-User (Ambulatory Surgery Centers, Clinics, Hospitals) - Forecast 2024-2030

  • PDF Icon

    Report

  • 183 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5675300
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The T-cell lymphoma Market size was estimated at USD 2.16 billion in 2023, USD 2.25 billion in 2024, and is expected to grow at a CAGR of 4.06% to reach USD 2.86 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the T-cell lymphoma Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the T-cell lymphoma Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the T-cell lymphoma Market, highlighting leading vendors and their innovative profiles. These include Acrotech Biopharma, LLC, Autolus Therapeutics PLC, Bausch Health Companies Inc., Bristol Myers Squibb Company, Citius Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Genmab A/S, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Kyowa Kirin Co., Ltd., Macopharma, Merck & Co. Inc., Novartis AG, Soligenix, Inc., and Spectrum Pharmaceuticals Inc.

Market Segmentation & Coverage

This research report categorizes the T-cell lymphoma Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Treatment
    • Chemotherapy
    • Corticosteroids
    • Retinoid
    • Topical Therapy
  • End-User
    • Ambulatory Surgery Centers
    • Clinics
    • Hospitals
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the T-cell lymphoma Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the T-cell lymphoma Market?
  3. What are the technology trends and regulatory frameworks in the T-cell lymphoma Market?
  4. What is the market share of the leading vendors in the T-cell lymphoma Market?
  5. Which modes and strategic moves are suitable for entering the T-cell lymphoma Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. T-cell lymphoma Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of t-cell lymphoma worldwide
5.1.1.2. Government initiatives to increase treatment awareness
5.1.1.3. Rising investments in healthcare infrastructure development
5.1.2. Restraints
5.1.2.1. High cost of t-cell lymphoma treatment and lack of reimbursement in developing economies
5.1.3. Opportunities
5.1.3.1. Research & development activities regarding t-cell lymphoma treatment
5.1.3.2. Advancements in combination therapies for peripheral T-cell lymphoma (PTCL)
5.1.4. Challenges
5.1.4.1. Lack of specific diagnostic characteristics
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. T-cell lymphoma Market, by Treatment
6.1. Introduction
6.2. Chemotherapy
6.3. Corticosteroids
6.4. Retinoid
6.5. Topical Therapy
7. T-cell lymphoma Market, by End-User
7.1. Introduction
7.2. Ambulatory Surgery Centers
7.3. Clinics
7.4. Hospitals
8. Americas T-cell lymphoma Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific T-cell lymphoma Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa T-cell lymphoma Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player
12. Competitive Portfolio
12.1. Key Company Profiles
12.1.1. Acrotech Biopharma, LLC
12.1.2. Autolus Therapeutics PLC
12.1.3. Bausch Health Companies Inc.
12.1.4. Bristol Myers Squibb Company
12.1.5. Citius Pharmaceuticals, Inc.
12.1.6. F. Hoffmann-La Roche Ltd.
12.1.7. Genmab A/S
12.1.8. GlaxoSmithKline PLC
12.1.9. Johnson & Johnson Services, Inc.
12.1.10. Kyowa Kirin Co., Ltd.
12.1.11. Macopharma
12.1.12. Merck & Co. Inc.
12.1.13. Novartis AG
12.1.14. Soligenix, Inc.
12.1.15. Spectrum Pharmaceuticals Inc.
12.2. Key Product Portfolio
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
List of Figures
FIGURE 1. T-CELL LYMPHOMA MARKET RESEARCH PROCESS
FIGURE 2. T-CELL LYMPHOMA MARKET SIZE, 2023 VS 2030
FIGURE 3. T-CELL LYMPHOMA MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. T-CELL LYMPHOMA MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. T-CELL LYMPHOMA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. T-CELL LYMPHOMA MARKET DYNAMICS
FIGURE 7. T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
FIGURE 8. T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 10. T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 12. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 14. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC T-CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC T-CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. T-CELL LYMPHOMA MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 20. T-CELL LYMPHOMA MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. T-CELL LYMPHOMA MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. T-CELL LYMPHOMA MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL T-CELL LYMPHOMA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 6. T-CELL LYMPHOMA MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. T-CELL LYMPHOMA MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. T-CELL LYMPHOMA MARKET SIZE, BY RETINOID, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. T-CELL LYMPHOMA MARKET SIZE, BY TOPICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 11. T-CELL LYMPHOMA MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. T-CELL LYMPHOMA MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. T-CELL LYMPHOMA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 15. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 16. AMERICAS T-CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 17. ARGENTINA T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 18. ARGENTINA T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 19. BRAZIL T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 20. BRAZIL T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 21. CANADA T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 22. CANADA T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 23. MEXICO T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 24. MEXICO T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 25. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 26. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 27. UNITED STATES T-CELL LYMPHOMA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 28. ASIA-PACIFIC T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 29. ASIA-PACIFIC T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 30. ASIA-PACIFIC T-CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 31. AUSTRALIA T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 32. AUSTRALIA T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 33. CHINA T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 34. CHINA T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 35. INDIA T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 36. INDIA T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 37. INDONESIA T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 38. INDONESIA T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 39. JAPAN T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 40. JAPAN T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 41. MALAYSIA T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 42. MALAYSIA T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 43. PHILIPPINES T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 44. PHILIPPINES T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 45. SINGAPORE T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 46. SINGAPORE T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 47. SOUTH KOREA T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 48. SOUTH KOREA T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 49. TAIWAN T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 50. TAIWAN T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 51. THAILAND T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 52. THAILAND T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 53. VIETNAM T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 54. VIETNAM T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 55. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 56. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 57. EUROPE, MIDDLE EAST & AFRICA T-CELL LYMPHOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 58. DENMARK T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 59. DENMARK T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 60. EGYPT T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 61. EGYPT T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 62. FINLAND T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 63. FINLAND T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 64. FRANCE T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 65. FRANCE T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 66. GERMANY T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 67. GERMANY T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 68. ISRAEL T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 69. ISRAEL T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 70. ITALY T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 71. ITALY T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 72. NETHERLANDS T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 73. NETHERLANDS T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 74. NIGERIA T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 75. NIGERIA T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 76. NORWAY T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 77. NORWAY T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 78. POLAND T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 79. POLAND T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 80. QATAR T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 81. QATAR T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 82. RUSSIA T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 83. RUSSIA T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 84. SAUDI ARABIA T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 85. SAUDI ARABIA T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 86. SOUTH AFRICA T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 87. SOUTH AFRICA T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 88. SPAIN T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 89. SPAIN T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 90. SWEDEN T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 91. SWEDEN T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 92. SWITZERLAND T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 93. SWITZERLAND T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 94. TURKEY T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 95. TURKEY T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 96. UNITED ARAB EMIRATES T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 97. UNITED ARAB EMIRATES T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 98. UNITED KINGDOM T-CELL LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM T-CELL LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 100. T-CELL LYMPHOMA MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 101. T-CELL LYMPHOMA MARKET SHARE, BY KEY PLAYER, 2023
TABLE 102. T-CELL LYMPHOMA MARKET LICENSE & PRICING

Companies Mentioned

  • Acrotech Biopharma, LLC
  • Autolus Therapeutics PLC
  • Bausch Health Companies Inc.
  • Bristol Myers Squibb Company
  • Citius Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genmab A/S
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Kyowa Kirin Co., Ltd.
  • Macopharma
  • Merck & Co. Inc.
  • Novartis AG
  • Soligenix, Inc.
  • Spectrum Pharmaceuticals Inc.

Methodology

Loading
LOADING...

Table Information